Osilodrostat
CAS No. 928134-65-0
Osilodrostat ( LCI699 )
产品货号. M19263 CAS No. 928134-65-0
Osilodrostat (LCI699) 是人 11β-羟化酶 (IC50: 2.5 nM) 和醛固酮合酶 (IC50: 0.7 nM) 的有效抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥432 | 有现货 |
|
| 5MG | ¥655 | 有现货 |
|
| 10MG | ¥1017 | 有现货 |
|
| 25MG | ¥1609 | 有现货 |
|
| 50MG | ¥2409 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥687 | 有现货 |
|
生物学信息
-
产品名称Osilodrostat
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Osilodrostat (LCI699) 是人 11β-羟化酶 (IC50: 2.5 nM) 和醛固酮合酶 (IC50: 0.7 nM) 的有效抑制剂。
-
产品描述Osilodrostat (LCI699) is an effective inhibitor of human 11β-hydroxylase (IC50: 2.5 nM) and aldosterone synthase (IC50: 0.7 nM).
-
体外实验——
-
体内实验Animal Model:Male Ang-II- and ACTH-stimulated Sprague Dawley rats Dosage:0.1, 0.3, 1 and 3 mg/kg (Ang-II-stimulated rats) and 1, 3, 10, 30 and 100 mg/kg (ACTH-stimulated rats) Administration:Oral administration; once Result:Inhibited the increase in plasma aldosterone concentrations stimulated by Ang II or ACTH in a dose-dependent manner.Animal Model:dTG rats Dosage:3, 10, 30 and 100 mg/kg Administration:Oral administration; daily, for 52 weeks Result:Increased fractional LV (systolic and diastolic) shortening, normalized LV isovolumic relaxation time to RR (IVRT/RR) ratio and myocardial cell size and reduced LV weight in a dose-dependent manner.
-
同义词LCI699
-
通路Metabolic Enzyme/Protease
-
靶点MAO
-
受体11β-hydroxylase,aldosterone synthase
-
研究领域Endocrinology
-
适应症——
化学信息
-
CAS Number928134-65-0
-
分子量227.24
-
分子式C13H10FN3
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 83.3 mg/mL; 366.57 mM
-
SMILESFc1cc(ccc1[C@H]1CCc2cncn12)C#N
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Li L, et al. Toxicol Appl Pharmacol. 2015 Aug 1;286(3):224-33.
021-51111890
购物车()
sales@molnova.cn

